section name header

Indications

High Alert


Jelmyto

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Interactions noted are for IV therapy only.

Availability

(Generic available)

Route/Dosage

IV and pyelocalceal (ureteral) formulations are not interchangeable.

US Brand Names

Jelmyto, Mutamycin

Action

  • Primarily inhibits DNA synthesis by causing cross-linking; also inhibits RNA and protein synthesis (cell-cycle phase-nonspecific but is most active in S and G phases).
Therapeutic effects:
  • Death of rapidly replicating cells, particularly malignant ones.

Classifications

Therapeutic Classification: antineoplastics

Pharmacologic Classification: antitumor antibiotics

Pharmacokinetics

Absorption: IV administration results in complete bioavailability. Bioavailability following pyelocalyceal administration unknown.

Distribution: Widely distributed, concentrates in tumor tissue. Does not enter CSF.

Metabolism/Excretion: Mostly metabolized by the liver. Small amounts (<10%) excreted unchanged by the kidneys and in bile.

Half-Life: IV: 50 min.

Time/Action Profile

(effects on blood counts)

ROUTEONSETPEAKDURATION
IV3–8 wk4–8 wkup to 3 mo



Patient/Family Teaching

Pronunciation

mye-toe-MYE-sin